Unilife, Hikma enter $40 million partnership
YORK, Pa. — Unilife Corp. has entered a deal with Hikma to launch 20 generic injectable drugs using Unilife’s pre-filled syringe technology, the two companies said Wednesday.
Under the 15-year agreement, Unilife will supply Hikma with its platform, including the Unifill syringe and the Unifill Nexus. Hikma has selected an initial list of 20 generic injectable products that it will include in the deal.
Under the deal, Hikma will pay Unilife $40 million, including $5 million upfront, $15 million in 2014 and $20 million in 2015.
"This agreement supports our strategy of developing higher-value products, and we are extremely pleased to be partnering with Unilife to develop our generic injectables capabilities," Hikma CEO Said Darwazah said. "We look forward to leveraging Unilife’s innovative platform of Unifill syringes to differentiate our injectable products and to increase our market share."
AlixaRx opens 11,400-sq.-ft. pharmacy hub
TOPEKA, Kan. — Gov. Sam Brownback of Kansas attended the grand opening of a new pharmacy hub that will serve post-acute patients in and around the state.
AlixaRx announced Wednesday the opening of the 11,400-sq. ft. Lenexa, Kan., hub, for which the company invested $1.4 million in new equipment and training and hired 42 employees. The hub will provide pharmacy services to nursing facilities in Kansas and neighboring states.
"Opening our AlixaRx pharmacy hub in Kansas allows us to bring a better medication delivery system to patients in post-acute and other healthcare settings," AlixaRx SVP Brad Savage said. "We appreciate the collaboration and support from Gov. Brownback and the state of Kansas. We look forward to expanding the employment and healthcare opportunity in the region."
Oral drugs gain on injectables in multiple sclerosis market, study finds
BURLINGTON, Mass. — Use of injectable drugs for multiple sclerosis declined during the 12-month period that ended on June 30 as orally administered drugs for the condition became more popular, according to a new report.
Healthcare industry research firm Decision Resources found that injected disease-modifying drugs for MS, such as Teva’s Copaxone (glatiramer acetate) and biotech drugs called interferon-betas, had a 70% share of the patient market in the second quarter of 2013, compared with 80% during the same period in 2012. A new drug made by Biogen Idec, Tecfidera, also captured a large portion of the patient population. Still, injectables captured 84% of patients undergoing first-line treatment.
"U.S. claims data confirm that time-tested injectables remain a core component of new MS treatment, overall and in treatment-naive patients, likely due in part to neurologists’ conservative adoption of new agents," Decision Resources senior director Jonathan Searles said. "That said, with oral DMTs capturing nearly 18% total patient share in the second quarter among patients in our sample who were recently treated, and with the use of Tecfidera surging, we anticipate continued steady losses among current mainstays over the near term."